Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Revenue (2021 - 2025)

Lyra Therapeutics has reported Revenue over the past 5 years, most recently at $7000.0 for Q4 2025.

  • Quarterly results put Revenue at $7000.0 for Q4 2025, down 96.65% from a year ago — trailing twelve months through Dec 2025 was $398000.0 (down 74.05% YoY), and the annual figure for FY2025 was $398000.0, down 74.05%.
  • Revenue for Q4 2025 was $7000.0 at Lyra Therapeutics, down from $25000.0 in the prior quarter.
  • Over the last five years, Revenue for LYRA hit a ceiling of $598000.0 in Q2 2024 and a floor of $7000.0 in Q4 2025.
  • Median Revenue over the past 5 years was $240000.0 (2021), compared with a mean of $285444.4.
  • Biggest five-year swings in Revenue: surged 2464.29% in 2022 and later plummeted 96.65% in 2025.
  • Lyra Therapeutics' Revenue stood at $271000.0 in 2021, then plummeted by 95.94% to $11000.0 in 2022, then skyrocketed by 1227.27% to $146000.0 in 2023, then skyrocketed by 43.15% to $209000.0 in 2024, then plummeted by 96.65% to $7000.0 in 2025.
  • The last three reported values for Revenue were $7000.0 (Q4 2025), $25000.0 (Q3 2025), and $183000.0 (Q2 2025) per Business Quant data.